Future work can test whether GPT-4 can improve the marginal performance of widely available clinical biomarkers such as C-reactive protein, assess the generalizability of FABP4/GPT-4 classifier performance in larger independent cohorts of ICU patients, and evaluate these methods for the diagnosis of other critical illness syndromes such as sepsis. This evidence concerns the gene CRP and Sepsis.